12:00 AM
 | 
Oct 25, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Herceptin trastuzumab regulatory update

FDA approved an sBLA from Roche's Genentech unit for Herceptin trastuzumab to treat HER2-positive metastatic stomach cancer, including gastro-esophageal junction cancer,...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >